Research
Comparing plasma p-tau217 and plasma p-tau217/Aβ 42 with CSF biomarkers for assessing Alzheimer’s disease pathology
Nature · By Noëlle Warmenhoven ·
The Brief
- A Nature Aging study compares blood tests for p-tau217 and p-tau217/Aβ42 with CSF biomarkers for assessing Alzheimer's disease pathology.
- The source describes the blood tests, including regulatory-authorized ones, as accessible and cost-effective diagnostic tools.
- The source excerpt is cut off before the full results, but it states the blood tests perform similarly to the CSF biomarkers.
Why it matters
If blood tests perform similarly to cerebrospinal fluid biomarkers, they could offer a less invasive and cheaper way to assess Alzheimer's pathology.
Who’s affected
- researchers and clinicians working on Alzheimer's disease
- people involved in dementia diagnosis and biomarker research
Nature Aging, Published online: 18 November 2026; doi:10.1038/s43587-026-01259-z Blood tests for Alzheimer’s disease, including regulatory authorized p-tau217 and p-tau217/AB42, are accessible and cost-effective diagnostic tools. This study shows that they perform similarly to…